Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 22.214.171.124) - Pipeline Review, H2 2018
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 126.96.36.199) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase - Pipeline Review, H2 2018, outlays comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 188.8.131.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 184.108.40.206) - Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM). Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K- and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Immunology and Metabolic Disorders which include indications Age Related Macular Degeneration, Breast Cancer, Dry (Atrophic) Macular Degeneration, Head And Neck Cancer, Inflammation, Refractory Multiple Myeloma, Retinopathy, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes and Wet (Neovascular / Exudative) Macular Degeneration.
Furthermore, this report also reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 220.127.116.11) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.